Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Testing the Addition of the Drug Nivolumab after Previous Therapy for High Risk Anal Cancer
- ClinicalTrials.gov Identifier: NCT03233711
- Protocol Number: 19-722
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required